Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Daiichi Sankyo
Argus Health
Merck
Baxter

Generated: September 19, 2019

DrugPatentWatch Database Preview

Selegiline - Generic Drug Details

  Try a free trial


See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for selegiline and what is the scope of selegiline patent protection?

Selegiline is the generic ingredient in four branded drugs marketed by Somerset, Apotex, Dava Pharms Inc, Lannett Co Inc, Rising, Bausch, Acp Nimble, Apotex Inc, Boscogen, Chartwell Molecules, G And W Labs Inc, Mylan, and Siegfried, and is included in seventeen NDAs. Additional information is available in the individual branded drug profile pages.

There are seventeen drug master file entries for selegiline. One supplier is listed for this compound.

Medical Subject Heading (MeSH) Categories for selegiline
Synonyms for selegiline
(-)-(N)-Methyl-N-((1R)-1-methyl-2-phenylethyl)prop-2-yn-1-amine
(-)-Deprenil
(-)-selegiline
(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine
(R)-(-)-N-Methyl-N-(1-phenyl-2-propyl)-2-propinylamin
(r)-(-)-n,2-dimethyl-n-2-propynylphenethylamine
(R)-(-)-N,alpha-Dimethyl-N-2-propinylphenethylamine
(R)-(-)-Selegiline
14611-51-9
14611-52-0 (hydrochloride)
172964-89-5
2079-54-1 (deprenyl.hydrochloride)
2K1V7GP655
AC1L1BTZ
AC1Q2860
AJ-74093
AKOS000281115
Anipryl
API0009080
Apo-Selegiline
BDBM15579
Benzeneethanamine, N,alpha-dimethyl-N-2-propynyl-, (R)-
Benzeneethanamine, N,alpha-methyl-N-2-propynyl-, (alphaR)-
BPBio1_000687
BRD-K86434416-001-02-7
BRD-K86434416-003-03-1
BRD-K86434416-003-06-4
BSPBio_000623
BSPBio_001589
C07245
Carbex
CHEBI:9086
CHEMBL972
D03731
DB01037
Deprenyl
DTXSID6023575
Eldepryl
Emsam
Emsam (TN)
FT-0688371
Gen-Selegiline
GTPL6639
HMS1791P11
HMS1989P11
HMS2089D09
HMS3402P11
Jumex
L-Deprenalin
L-Deprenyl
l-E 250
LS-30156
methyl[(2R)-1-phenylpropan-2-yl](prop-2-yn-1-yl)amine
methyl[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-ylamine
MEZLKOACVSPNER-GFCCVEGCSA-N
N-methyl-N-[(1R)-1-methyl-2-phenylethyl]prop-2-yn-1-amine
N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine
NCGC00024994-01
NCGC00024994-02
NCGC00024994-03
NCGC00024994-04
Novo-Selegiline
Nu-Selegiline
Otrasel
Prestwick0_000552
Prestwick1_000552
Prestwick2_000552
Prestwick3_000552
R(-)-Selegiline solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
SCHEMBL22232
Sd Deprenyl
Selegeline Hcl
Selegene
Selegilina
Selegilina [INN-Spanish]
Selegiline (USAN/INN)
Selegiline [INN:BAN]
Selegiline [USAN:INN:BAN]
Selegiline Transdermal System (STS) patch
Selegiline, (R)-Isomer
Selegilinum
Selegilinum [INN-Latin]
Selegyline
selgene
SPBio_002544
STK640578
UNII-2K1V7GP655
UNII-DPF682Q08V component MEZLKOACVSPNER-GFCCVEGCSA-N
US8633208, Deprenyl
Yumex
Zalapar
Zelapar
ZINC19632633

US Patents and Regulatory Information for selegiline

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acp Nimble SELEGILINE HYDROCHLORIDE selegiline hydrochloride TABLET;ORAL 074756-001 Nov 25, 1998 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Siegfried SELEGILINE HYDROCHLORIDE selegiline hydrochloride TABLET;ORAL 074672-001 Apr 1, 1997 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-002 Feb 27, 2006 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
G And W Labs Inc SELEGILINE HYDROCHLORIDE selegiline hydrochloride TABLET;ORAL 074537-001 Aug 2, 1996 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Chartwell Molecules SELEGILINE HYDROCHLORIDE selegiline hydrochloride TABLET;ORAL 074565-001 Aug 2, 1996 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Apotex Inc SELEGILINE HYDROCHLORIDE selegiline hydrochloride TABLET;ORAL 074871-001 Jun 6, 1997 AB RX No Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for selegiline

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-003 Feb 27, 2006 ➤ Sign Up ➤ Sign Up
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-003 Feb 27, 2006 ➤ Sign Up ➤ Sign Up
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-001 Feb 27, 2006 ➤ Sign Up ➤ Sign Up
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-002 Feb 27, 2006 ➤ Sign Up ➤ Sign Up
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-001 Feb 27, 2006 ➤ Sign Up ➤ Sign Up
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-001 Feb 27, 2006 ➤ Sign Up ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Healthtrust
Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.